| 摘要 |
PROBLEM TO BE SOLVED: To provide pharmaceutical compositions for the prevention, delay of progression, or treatment of a disease or condition which is selected from chylomicronemia syndrome, familial chylomicronemia syndrome and Type V hyperlipoproteinemia.SOLUTION: The invention provides a DGAT1 inhibitor containing trans-4-[4-[5-[[6-(trifluoromethyl)-3-pyridinyl] Amino]-2-pyridinyl] phenyl] cyclohexaneacetic acid or pharmaceutically acceptable salt or ester thereof. The DGAT1 inhibitor is preferably the Na salt of the compound represented by the following formula.SELECTED DRAWING: None |
